Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EPS (Weighted Average and Diluted) (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.22 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 75.7% year-over-year to -$1.22; the TTM value through Sep 2025 reached $32.01, up 170.8%, while the annual FY2024 figure was -$11.89, 50.97% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.22 in Q3 2025 per ZBIO's latest filing, up from -$1.25 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $35.28 in Q4 2024 and bottomed at -$24.26 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1.65, with a median of -$1.23 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 356.12% in 2024, then soared 95.53% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $1.96 in 2023, then skyrocketed by 1700.0% to $35.28 in 2024, then crashed by 103.46% to -$1.22 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.22 in Q3 2025, -$1.25 in Q2 2025, and -$0.8 in Q1 2025.